Traws Pharma reports Q2 net loss of $123.1M; $16.9M cash; pipeline milestones ahead

Traws Pharma, Inc.

2024-Q2 EPS reported -$5.53 revenue$113,000

Net loss of $123.1M ($4.87 per share) includes $117.5M non-cash charge from acquired in-process R&D.
Cash, cash equivalents and short-term investments of $16.9M as of June 30, 2024; adequate through year-end.
Merger with Trawsfynydd completed April 2024; concurrent $14M private placement from Orbimed and Torrey Pines.
Tivoxavir marboxil (influenza) Phase 1 dose extension underway; topline results expected Q4 2024.
Ratutrelvir (COVID-19) completed Phase 1 SAD/MAD; Phase 2 initiation planned Q4 2024/Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.